Tirzepatide, an agonist of glucose-dependent insulinotropic polypeptide and GLP-1 approved for treatment of T2D, showed promising improvements in MASH during the phase 2 randomized trial [187]. This evidence concerns the gene GIP and type 2 diabetes mellitus.